Business of the House

Tom Randall Excerpts

Thursday 21st January 2021 Commons Chamber

[Mr Rees-Mogg]

The hon. Lady is right to raise this issue, which is one of concern across the House; the seriousness of flooding and the effect that it has on families and businesses is very severe. My right hon. Friend the Secretary of State for Environment, Food and Rural Affairs was here answering questions earlier and I know how hard he is working. As I walked to my office, I overheard him on the telephone, just before coming in to answer questions, trying to get more done to help people who are at risk of flooding. He is working tirelessly and the Government policy is there to help people. Some £5.2 billion will be spent on flood and coastal defences, which is double the previous amount, helping 336,000 properties over the next six years, in addition to the 300,000 properties that have been helped since 2015. I accept that if people have been flooded within the last 24 hours, the promise of £5.2 billion being spent is not a great comfort, but I can say that action is being taken to ensure that people will be safer in future.

[Tom Randall (Gedling) (Con) [V]]

At six months old, Hurley is one of my youngest constituents, but he has PKU—phenylketonuria—a medical condition where his body cannot process protein, which severely restricts his diet. Most ordinary food will be off limits. There is a treatment available called Kuvan that can be transformative, and it is available in many other European countries but not here. Can we have some parliamentary time to debate the challenges facing those with PKU and how we can ensure that the one in 10,000 babies born with it get the best possible treatment?

[Mr Rees-Mogg]

May I say how much I sympathise with my hon. Friend? Just before I entered Government, I had a case of a young child who needed a very expensive and unusual drug, and I am very glad to say that, in the end, that child got it. I encourage my hon. Friend to use every parliamentary mechanism he can possibly think of to campaign for this child. It is so important that we help our young constituents, who have long lives ahead of them.

Such issues are decided by the National Institute for Health and Care Excellence, which is the independent body responsible for providing evidence-based guidance for the NHS on whether medicines represent a clinical and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended through a NICE appraisal, usually within three months of final guidance. NICE is currently appraising Kuvan for PKU and aims to publish its recommendation in April. My hon. Friend may also wish to be aware that applications for generic versions of the drug may now be submitted.

Following the UK’s exit from the European Union, the Medicines and Healthcare Products Regulatory Agency is the UK’s stand-alone medicines regulator and has introduced an accelerated national assessment procedure. That is open to applications for generic medicines, as well as innovative medicines, and in a timeframe to reach a licensing decision in 150 days rather than the 200-day EU procedure. However, I have such sympathy with my hon. Friend and with the child and family in question, and I encourage him to keep knocking on everybody’s door.